Assessment of association between Clinical score and the treatment outcome in terms of progression free survival in patients with well differentiated Neuroendocrine tumors receiving PRRT with Lu 177-dotatate
Latest Information Update: 02 Mar 2021
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Intestinal cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- 02 Mar 2021 New trial record
- 17 Jan 2021 Results presented at the 2021 Gastrointestinal Cancers Symposium